2006: A Stroke Odyssey

American Journal of Neuroradiology

Volumn 27, Issue 10, 2006, Pages 2019-2021

  Tomsick, Thomas A ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; CONTRAST MEDIUM; NEUROPROTECTIVE AGENT;

BLOOD CLOT LYSIS; BRAIN ANGIOGRAPHY; BRAIN EMBOLISM; BRAIN HEMATOMA; BRAIN HEMORRHAGE; CAROTID ARTERY OBSTRUCTION; CATHETERIZATION; CEREBRAL ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTRAST MEDIUM EXTRAVASATION; DEATH; DEVICE REMOVAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; ECHOGRAPHY; HUMAN; INFUSION RATE; MIDDLE CEREBRAL ARTERY OCCLUSION; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NOTE; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PATIENT SELECTION; RANKIN SCALE; RECANALIZATION; REVASCULARIZATION; RISK ASSESSMENT; STROKE; TREATMENT DURATION; TREATMENT RESPONSE;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS, PHASE III; FIBRINOLYTIC AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33751237366     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (16)

1. Smith W, Sung G, Starkman S, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005;36:1432-40
2. Haley EC, Levy DE, Brott TG, et al. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992;23:641-45
3. Brott TG, Haley EC, Levy DE, et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992;23:632-40
4. Tomsick T, Brott T, Barsan W, et al. Prognostic value of the hyperdense middle cerebral artery sign and stroke scale score before ultra-early thrombolytic therapy. AJNR Am J Neuroradiol 1996;17:79-85
5. Zeumer H, Freitag HJ, Zanella F, et al. Local intra-arterial fibrinolytic-therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (r-TPA). Neuroradiology 1993;35:159-62
6. Tomsick TA. Sensitivity and prognostic value of early CT in occlusion of the middle cerebral artery trunk. AJNR Am J Neuroradiol 1994;15:16-18
7. Lewandowski C, Frankel M, Tomsick T, et al, and the EMS Bridging Trial Investigators. Combined intravenous and intra-arterial r-tPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke 1999;30:2598-605
8. The NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-87
9. Furlan A, Higashida R, Weschler L, et al. Intra-arterial prourokinase for acute ischemic stroke: The PROACT II Study-a randomized controlled trial, Prolyse in Acute Cerebral Thromboembolism. JAMA 1999;282:2003-11
10. Flaherty ML, Woo D, Kissells B, et al. Combined IV and intra-arterial thrombolysis for acute ischemic stroke. Neurology 2005;64:386-88
11. The IMS investigators. Combined intravenous and intraarterial recanalization for acute ischemic stroke: the interventional management of stroke study. Stroke 2004;35:904-12
12. Mahon BR, Nesbit GM, Barnwell SL, et al. North American clinical experience with the EKOS MicroLysUS infusion catheter for the treatment of stroke. AJNR Am J Neuroradiol 2003;24:534-38
13. IMS II investigators. Preliminary results of IMS II Trial [abstract]. Stroke 2006;37:708
14. Berger C, Fiorelli M, Steiner T, et al. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? Stroke 2001;32:1330-35
15. Khatri P, Broderick JP, Khoury J, et al. Microcatheter contrast injections during intra-arterial thrombolysis increase intracranial hemorrhage risk [abstract]. Stroke 2006;37:622
16. Lees KR, Zivin JA, Ashwood T, et al. NXY-059 for acute ischemic stroke. N Engl J Med 2006;354:588-600